AZD7762, a Checkpoint Kinase-1 (Chk1) inhibitor, can enhance cisplatin sensitivity in p53-deficient HNSCC cells by inducing mitotic cell death.33 The gene discussed is CHEK1; the disease is head and neck squamous cell carcinoma.